AstraZeneca discloses oral pharmaceutical compositions combining SGLT2 inhibitors with mineralocorticoid receptor modulators to treat heart failure and/or chronic kidney disease.

Patentradars sammanfattning

This divisional European patent application (EP 4 778 578 A2) from AstraZeneca AB covers pharmaceutical compositions and oral dosage forms that combine SGLT2 inhibitors (e.g., dapagliflozin class, A61K 31/538) with mineralocorticoid receptor modulators for the treatment of heart failure and chronic kidney disease. The formulations are characterized by specific pellet/bead technologies (A61K 9/1611, 9/1623, 9/1635, 9/1652, 9/1676) and capsule delivery systems (A61K 9/4825, 9/4858), indicating a modified-release or multiparticulate oral dosage form strategy. The combination targets two mechanistically complementary pathways—SGLT2-mediated glycosuric/cardio-renal protection and aldosterone receptor antagonism—to address cardiorenal syndrome. Priority dates trace to US provisional applications filed September 2022 and August 2023.

AI-genererad och redaktionellt processad.